Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 787

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 787
---
 term or the estimated useful life of the asset. Property and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Noimpairment was recorded for the period ended September 30, 2024, nor the year ended December 31, 2023. Lease Accounting– The Company recognizes right-of-uselease assets and corresponding liabilities arising from leasing activities over the requisite lease period. Income Taxes– Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. In December 2023, the FASB issued ASU No. 2023-09,Income Taxes ( Topic 740), which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU 2023-09,public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU 2023-09are effective fiscal years beginning after December 31, 2024, and early adoption is permitted. The Company does not believe that the adoption of ASU 2023-09will have a material impact on its condensed consolidated financial statements. Research and Development Expenses– Research and development consists of expenses incurred in connection with the discovery and development of product candidates. The Company expenses research and development costs as incurred. Acquired In-ProcessResearch and Development –Acquired in-processresearch and development expenses consist of existing research and development projects at the time of the acquisition. Projects that qualify as IPR&D assets represent those that have not yet reached technological feasibility and had no alternative future use, which resulted in a write-offof these IPR&D assets to acquired in-processresearch and development expenses in our consolidated statements of operations. Concentration of Credit Risk– The Company maintains cash balances in domestic financial institutions. These balances are insured by the Federal Deposit Insurance Corporation up to $ 250,000. As of September 30, 2024, the uninsured portion of cash held by the Company was approximately $ 18,813,000. F- 69

TUHURA BIOSCIENSES, INC AND SUBSIDIARY Notes to the condensed consolidated financial statements For the nine months ended September 30, 2024, and 202